hVIVO PLC | Cash Flow

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
1,193.00
22,705.00
21,625.00
22,631.00
14,817.00
18,856
Depreciation, Depletion & Amortization
814.00
1,656.00
1,660.00
1,603.00
1,482.00
710
Other Funds
700.00
75.00
75.00
75.00
75.00
9,616
Funds from Operations
939.00
14,753.00
15,885.00
9,191.00
8,456.00
8,530
Changes in Working Capital
3,019.00
1,485.00
6,437.00
8,331.00
3,462.00
1,707
Net Operating Cash Flow
2,080.00
16,238.00
9,448.00
17,522.00
4,994.00
6,823
Capital Expenditures
4,183.00
1,503.00
884.00
822.00
321.00
Sale of Fixed Assets & Businesses
-
67.00
-
-
-
Purchase/Sale of Investments
-
5,507.00
18,429.00
29,893.00
-
Net Investing Cash Flow
26,683.00
6,943.00
19,313.00
29,071.00
321.00
Net Financing Cash Flow
25,687.00
32,705.00
20,130.00
75.00
75.00
Net Change in Cash
3,028.00
9,516.00
8,621.00
11,474.00
5,390.00
Free Cash Flow
5,182.00
17,593.00
10,317.00
17,684.00
5,044.00
Change in Capital Stock
24,987.00
32,780.00
20,205.00
-
-
Exchange Rate Effect
48.00
8.00
10.00
-
-
Other Uses
22,500.00
-
-
-
-

About hVIVO

View Profile
Address
Queen Mary BioEnte Innovation Centre
London London & South East E1 2AX
United Kingdom
Employees -
Website http://retroscreen.com
Updated 07/08/2019
hVIVO Plc is an investment holding company, which engages in the provision of human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. It focuses on medical and scientific research services. The company was founded by John Sidney Oxford on March 27, 2012 and is headquartered in London, the United Kingdom.